Immune pathway
Alpha Thymosin
Single-component reagent
Laboratory verification
Nothing unverified is published
Every compound is prepared to a documented standard. Independent certificates of analysis are published here per batch as they are verified under Nuragen's own governance, we do not reuse another brand's certificates or purity figures.
Certificate of analysis · per batch · on request
Verification-led release
Alpha Thymosin is a single-component research reagent containing Thymosin Alpha-1, a naturally occurring thymic peptide. It is studied in the immune-modulation research literature and supplied strictly for research use only.
How it is studied
Thymosin Alpha-1 is examined in laboratory research concerned with immune signalling and the regulation of immune cell activity. In the research literature it is associated with the modulation of T-cell and dendritic-cell pathways, and it is used as a defined reference compound in controlled experimental settings. NURAGEN supplies it as a discrete single component so that its behaviour can be characterised without confounding constituents. All work described here relates to in-vitro and preclinical research contexts, not to any human or animal use.
The component and the pathway
This reagent contains one component: Thymosin Alpha-1, a 28-amino-acid peptide corresponding to a fragment of the naturally occurring thymic protein prothymosin alpha. It is categorised within the immune pathway, where it is thought to act on signalling processes involved in immune-cell maturation and regulation. Being a single-component reagent, its composition is deliberately simple, which supports reproducibility and clear attribution of any observed effects. Any described activity reflects mechanisms reported in the research literature, not an outcome for a person.
How it sits in a responsible research programme
Within a responsible programme, Thymosin Alpha-1 is treated as a defined variable: handled under documented conditions, referenced against the published literature, and interpreted only in the context of the study design. Evidence is gathered before conclusions are drawn, and process is described in mechanistic terms rather than promised outcomes. NURAGEN provides the reagent and its factual description; the design, conduct and interpretation of any study remain the responsibility of the qualified researcher.
Composition
| Component | CAS | Purity |
|---|---|---|
| Thymosin Alpha-1 | 62304-98-7 | Pending |
| Type | Lyophilised powder |
|---|---|
| Presentation | Lyophilised powder |
| Appearance | White lyophilised powder |
| Storage | Store at 2-8°C, protected from light. |
| Dispatch | Delivered within 72 hours across the UK. |
Handling should follow standard laboratory practice and your own institutional protocols. No dosing, administration or medical guidance is provided.
Alpha Thymosin is a single-component research reagent containing Thymosin Alpha-1, a naturally occurring thymic peptide studied in immune-modulation research. It is supplied strictly for research use only and is not intended for human or animal use, diagnosis, or any therapeutic application.
Handling and storage should follow standard laboratory practice for peptide reagents. As a general guide, it is typically kept refrigerated at 2-8C and protected from light, with prolonged exposure to light, heat and repeated temperature fluctuation avoided. Always defer to your own institutional protocols and any documentation accompanying the material.
No. NURAGEN provides a factual description of what the compound is and what it is studied to do in the research literature. We do not provide dosing, administration guidance, treatment protocols, or medical advice of any kind. Study design and interpretation remain the responsibility of the qualified researcher.
Thymosin Alpha-1 is categorised within the immune pathway. In the research literature it is associated with the modulation of immune signalling and is thought to act on processes involved in the maturation and regulation of immune cells. Any activity described reflects reported mechanisms in a research context, not an outcome for an individual.
In context
Evidence before action
Thymosin Alpha-1 has a long presence in the immune-research literature, which is exactly why it warrants careful, evidence-led handling rather than assumption. A peptide that signals within immune pathways can behave differently across models, concentrations and experimental conditions, so what is observed in one setting should not be generalised to another. Responsible practice means grounding each study in the published mechanism, controlling variables, and letting the data speak before any interpretation is made. NURAGEN describes what this compound is and what it is studied to do; the reasoning always follows the evidence, not the other way around.
Related pathways
Explore alongside
Recovery
Thymosin Beta-4
Single-component Thymosin Beta-4 reagent, studied within recovery-pathway and tissue-repair research.
£150
Recovery
Repair
A focused research pair of BPC-157 and TB-500, studied within tissue-repair pathways.
£140
Longevity
Regenesis
Proprietary multi-component longevity blend studied for research use only.
£270
Longevity
Cellular Energy
NAD+ coenzyme studied in cellular energy metabolism and repair pathways.
£150